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A commentary on
A hypothesis for examining skeletal muscle biopsy-derived sarcolemmal nNOSμ as surrogate 
for enteric nNOSα function
by Chaudhury A. Front Med (2015) 2:48. doi: 10.3389/fmed.2015.00048
Dr. Chaudhury puts forward an interesting hypothesis that reductions in sarcolemmal nNOSμ 
might parallel reductions in enteric neuron nNOSα expression, localization, and activity (1). In 
other words, nNOSμ expressed at the plasma membrane (sarcolemma) of skeletal muscle cells could 
act as a surrogate for nNOSα function. This possibility is attractive because sarcolemmal nNOSμ 
localization and expression can be readily assessed from peripheral skeletal muscle biopsies. Also, 
this possibility is enticing because it circumvents the difficulties of obtaining gastrointestinal tract 
biopsies to evaluate nNOSα dysregulation as a potential causal factor of gut dysfunction. We aim to 
advance the dialog on this issue by addressing key assumptions of this hypothesis from the point of 
view of skeletal muscle nNOS.
Key assumptions of this hypothesis include (1) the molecular similarity of the nNOSα and nNOSμ 
splice variants; (2) the mechanisms regulating nNOSα localization in neurons are similar to those regu-
lating nNOSμ in skeletal muscle cells. The molecular similarity assumption is reasonably based on high 
protein homology between nNOSα and nNOSμ. Muscle nNOSμ contains an internal 34 amino acid 
insert in the autoregulatory domain not found in nNOSα (2). And while the study of isozyme-specific 
differences between nNOS splice variants is in its infancy, early studies suggest that μ insert inclusion 
reduces the speed of electron transfer from reductase to oxidase domains (3). The physiological signifi-
cance of this altered catalytic activity of nNOSμ relative to nNOSα remains to be determined. From an 
evolutionary point of view, there has been positive selective pressure to retain both nNOSα and nNOSμ 
splice variants strongly suggesting key functional differences that confer advantage. Therefore, caution 
must be exercised to avoid overestimating the similarities of nNOSα and nNOSμ.
In addition, it is important not to overlook additional differences at the transcript level between 
nNOSα and nNOSμ, particularly in humans, due to alternative amino terminal exon choice that do 
not impact protein sequence. This provides additional molecular differences between nNOSα and 
nNOSμ and suggests potential mechanisms of differential control between nNOS splice variants-
particularly between neurons and skeletal muscle cells (4). Transcript diversity represents an impor-
tant regulatory mechanism for the control of tissue-specific distribution and function of NOS1 gene 
splice variants and is an important consideration for understanding nNOS isozyme function salient 
to Dr. Chaudhury’s hypothesis.
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The second key assumption is that similar mechanisms act to 
localize nNOSα in neurons and nNOSμ in skeletal muscle cells. 
Before discussing this point, it is worth describing the multiple 
spatially and functionally distinct pools of nNOS in skeletal muscle 
cells. Two functionally and spatially distinct nNOS splice variants 
are co-expressed in skeletal muscle cells-nNOSβ and nNOSμ (5, 6). 
We consider nNOSμ only here. Although the sarcolemmal locali-
zation of nNOSμ is well recognized, it is commonly overlooked 
that sarcolemmal nNOSμ represents not more than half of total 
nNOSμ expressed in skeletal muscle cells. Furthermore, a small 
fraction of that sarcolemmal nNOSμ resides on the postsynaptic 
membranes of skeletal muscle cells at the neuromuscular synapse. 
In addition, approximately half of muscle nNOSμ is localized to 
the cytosol where it regulates RYR1-mediated calcium release from 
the sarcoplasmic reticulum (7). Importantly, cytosolic nNOSμ is 
quite active in resting muscles; arguing against the proposition 
that nNOSμ requires localization to the sarcolemma to be active. 
This is not to say that the localization nNOSμ is not critical for 
some its functions in skeletal muscle, such as the attenuation of 
sympathetic vasoconstriction during exercise (8). We are say-
ing that in skeletal muscle, nNOSμ does not have to be at the 
plasma membrane to be active and that nNOSμ has important 
non-sarcolemmal functions. Perhaps most importantly, the pool 
of nNOSμ at the neuromuscular junction in skeletal muscle may 
be the most relevant for comparison with enteric neuron nNOSα.
The localization of sarcolemmal nNOSμ is relatively well 
understood. In skeletal muscle, α-syntrophin is a critical and nec-
essary scaffold for nNOSμ at the sarcolemma and neuromuscular 
synapse. By contrast, post synaptic density 95 (PSD-95) protein is 
the key scaffold in different neuronal cells of the central nervous 
system (9). Therefore, there is a critical difference in mecha-
nisms used to localize plasma membrane-associated nNOS in 
neurons and skeletal muscle cells. This of course undermines the 
strength of the second key assumption of the hypothesis that the 
mechanisms localizing nNOS at the plasma membrane in skeletal 
muscle cells in neurons are similar enough.
However, of greater relevance and importance to the 
hypothesis is that the sarcolemmal localization of nNOSμ and 
its expression in skeletal muscle is dynamic [reviewed in Ref. 
(6, 10)]. The expression of nNOSμ and its association with 
the sarcolemma positively correlates with activity or exercise 
level in rodents and humans and may be a useful biomarker 
of exercise capacity. With greater activity, typically endurance 
type exercise, there is an increased expression of nNOSμ at the 
sarcolemma. Conversely, with a decrease in activity associated 
with conditions such as myopathy, chronic bedrest, or hindlimb 
unloading, nNOSμ translocates from the plasma membrane to 
the cytosol and can initiate a muscle wasting atrogene program 
by mechanisms that remain to be fully deciphered (10). In other 
words, nNOSμ appears to participate in a “use it or lose it” type 
mechanism to control muscle mass and exercise capacity. The 
molecular details underpinning this mechanism remain to be 
fully deciphered. However, this muscle-specific activity-based 
control of nNOSμ may confound the use of sarcolemmal nNOSμ 
as a proxy for enteric neuron nNOSα. It is quite likely that 
patients with severe gastrointestinal motility disorders will be 
more sedentary and perhaps exhibit reduced exercise tolerance, 
particularly if they lack normal nNOSμ activity. Therefore, as 
a secondary downstream consequence we would expect their 
skeletal muscles to express less sarcolemmal nNOSμ. In this 
scenario, these patients would always have less sarcolemmal 
nNOSμ. In other words, nNOSμ levels would reflect patient 
activity levels and not neuronal nNOSα making the evaluation 
of sarcolemmal nNOSμ uninformative as a surrogate for nNOSα 
in the gastrointestinal tract.
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